The EA sample (N=2596) was used in all parts of the analytical framework, which included (1) development of a phenotypic factor comprised of shared variance among DSM-5 items using randomly selected individuals to create two halves of the sample for exploratory and confirmatory models (conducted in Mplus version 7) (Muthén and Muthén, (1998–2012)), (2) Genomic-relatedness-matrix restricted maximum likelihood (GREML; implemented in GCTA) analysis of the individual symptoms, AUD factor score (standardized [mean=0, standard deviation=1]), AUD diagnosis (i.e., 0=0–1 symptoms, 1=2–11 symptoms), and log-transformed DSM-5 AUD diagnosis severity (i.e., Ln(1+DSM-5 AUD diagnosis [0=0–1 symptoms, 1=mild [2–3 symptoms], 2=moderate[4–5 symptoms], 3=severe [7+ symptoms]]).
